文献速递肝病

靶向白蛋白治疗未改善肝硬化低钠血症住院患者短期结局:ATTIRE试验数据

Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究基于ATTIRE试验数据,分析靶向白蛋白输注对基线低钠血症(血钠<130 mmol/L)的失代偿期肝硬化住院患者结局的影响。随机接受白蛋白治疗显著升高血钠,但钠分类与治疗对主要复合终点无交互作用,提示靶向白蛋白未改善短期结局。

要点

  • 靶向白蛋白输注显著升高肝硬化低钠血症患者血钠水平
  • 血钠分类与治疗对主要复合终点无显著交互作用
  • 白蛋白升高血钠未转化为短期临床结局改善

核心结论

  • 靶向静脉白蛋白输注可升高肝硬化低钠血症住院患者血钠,但未改善短期结局。

研究设计与样本

  • 基于ATTIRE试验数据的分析,按基线血钠≥或<130 mmol/L分层,检验靶向白蛋白与标准治疗对复合主要终点的交互作用。

主要发现

  • 随机接受白蛋白治疗与血钠显著升高相关。
  • 血钠分类与治疗对试验主要终点无交互作用。

关键数值与推荐

  • 分层阈值为基线血钠≥和<130 mmol/L。

临床怎么用

  • 对肝硬化低钠血症住院患者,不应仅以升高血钠为目的常规使用靶向白蛋白治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with decompensated cirrhosis and hyponatremia have a poor prognosis. We investigated Albumin to Prevent Infection in Chronic Liver Failure trial data to determine whether targeted albumin infusions improved outcome in patients with hyponatremia at baseline. METHODS: We examined the interaction between targeted albumin and standard care for the composite primary end point, stratifying by baseline sodium ≥ and <130 mmol/L. RESULTS: Randomization to albumin was associated with a significant increase in sodium; however, there was no interaction between sodium category and treatment for the trial primary end point. DISCUSSION: Targeted intravenous albumin infusions increased serum sodium level in hospitalized hyponatremic patients with cirrhosis, but this did not improve outcome.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. China L, Freemantle N, Forrest E, et al. Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial. Am J Gastroenterol. 2021. PMID: 34520431. doi:10.14309/ajg.0000000000001488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。